Systematic (IUPAC) name | |
---|---|
(R)-N-[1-(1-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-1-amine |
|
Clinical data | |
AHFS/Drugs.com | monograph |
MedlinePlus | a605004 |
Licence data | EMA:Link, US FDA:link |
Pregnancy cat. | B3(AU) C(US) |
Legal status | ℞ Prescription only |
Routes | Oral |
Pharmacokinetic data | |
Bioavailability | 20 to 25% Increases if taken with food |
Protein binding | 93 to 97% |
Metabolism | Hepatic (CYP3A4-, CYP2D6- and CYP1A2-mediated) |
Half-life | 30 to 40 hours |
Excretion | Renal (80%) and fecal (15%) |
Identifiers | |
CAS number | 226256-56-0 |
ATC code | H05BX01 |
PubChem | CID 156419 |
DrugBank | APRD00872 |
ChemSpider | 137743 |
UNII | UAZ6V7728S |
KEGG | D03504 |
ChEBI | CHEBI:48390 |
ChEMBL | CHEMBL1201284 |
Chemical data | |
Formula | C22H22F3N |
Mol. mass | 357.412 g/mol |
SMILES | eMolecules & PubChem |
|
|
(verify) |
(what is this?)
Cinacalcet (INN) is a drug that acts as a calcimimetic (i.e. it mimics the action of calcium on tissues) by allosteric activation of the calcium-sensing receptor that is expressed in various human organ tissues. It is sold by Amgen under the trade name Sensipar in North America and Australia and as Mimpara in Europe. Cinacalcet is used to treat secondary hyperparathyroidism (elevated parathyroid hormone levels), a consequence of having end-stage renal disease.[1] Cinacalcet is also indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.[2]
Contents |
Cinacalcet is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis and hypercalcemia in patients with parathyroid carcinoma.
B.C. Van Wagenen, S.T. Moe, M.F. Balandrin, E.G. DelMar, E.F. Nemeth, U.S. Patent 6,211,244 (2001).
|